AstraZeneca PLC (AZN)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

The chart shows the growth of an initial investment of $10,000 in AstraZeneca PLC, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.

AstraZeneca PLC (AZN) has returned 9.51% so far this year and 37.92% over the past 12 months. Looking at the last ten years, AZN has achieved an annualized return of 16.71%, outperforming the S&P 500 Index benchmark, which averaged 12.16% per year.

Based on dividend-adjusted daily data since May 17, 1993, AZN's average daily return is +0.06%, while the average monthly return is +1.25%. At this rate, your investment would double in approximately 4.6 years.

Historically, 54% of months were positive and 46% were negative. The best month was Mar 2000 with a return of +23.9%, while the worst month was Aug 2002 at -19.7%. The longest winning streak lasted 7 consecutive months, and the longest losing streak was 6 months.

On a daily basis, AZN closed higher 51% of trading days. The best single day was Oct 14, 2002 with a return of +12.4%, while the worst single day was Aug 19, 2002 at -16.3%.

AstraZeneca PLC has an annualized alpha of 10.44%, beta of 0.60, and R² of 0.18 versus S&P 500 Index. Calculated based on daily prices since May 18, 1993.

• This stock participates in less of S&P 500 Index's moves in both directions, but captures a larger share of gains (80.03%) than losses (53.82%) — typical of diversified or defensive assets.
• Beta of 0.60 may look defensive, but with R² of 0.18 this stock is largely uncorrelated with S&P 500 Index — low beta reflects independence, not downside protection. See the Volatility section for a true picture of this stock's risk.
• R² of 0.18 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

AZN ranks 82 for risk / return — in the top 82% of stocks on our site. This means strong returns relative to risk — exactly what professional investors look for. Well-suited for investors who want to maximize return per unit of risk.

The table below present risk-adjusted performance metrics for AstraZeneca PLC (AZN) and compare them to a chosen benchmark (S&P 500 Index).

AstraZeneca PLC provided a 2.70% dividend yield over the last twelve months, with an annual payout of $5.33 per share. The company has been increasing its dividends for 4 consecutive years.

The table displays the monthly dividend distributions for AstraZeneca PLC. The dividends shown in the table have been adjusted to account for any splits that may have occurred.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the AstraZeneca PLC. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the AstraZeneca PLC was 48.94%, occurring on Mar 9, 2009. Recovery took 977 trading sessions.

The current AstraZeneca PLC drawdown is 5.39%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of AstraZeneca PLC over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how AstraZeneca PLC is priced in the market compared to other companies in the Drug Manufacturers - General industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.